Saranya Dinesan
Jackson, MSNPI 1568925469
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.
Across 122 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$267
- Incyte Corporation$237
- Bristol Myers Squibb$230
- AstraZeneca$193
- Johnson & Johnson$177
- Takeda Pharmaceuticals U.S.A., Inc.$171
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,509100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $267 |
| Incyte Corporation | 12 | $237 |
| Bristol Myers Squibb | 10 | $230 |
| AstraZeneca(2 entities) | 7 | $193 |
| Johnson & Johnson(2 entities) | 10 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $171 |
| Astellas Pharma US Inc | 8 | $162 |
| Pfizer | 6 | $109 |
| Sanofi | 6 | $108 |
| Gilead(2 entities) | 2 | $94 |
| Merck | 5 | $92 |
| GSK | 4 | $81 |
| AVEO Pharmaceuticals, Inc. | 3 | $67 |
| Taiho Oncology, Inc. | 2 | $66 |
| Sobi, Inc | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Novo Nordisk | 2 | $46 |
| Array Biopharma Inc | 2 | $35 |
| Boehringer Ingelheim | 2 | $35 |
| Geron Corporation | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Bayer | 1 | $18 |
| EMD Serono, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Genmab U.S., Inc. | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $14 |
| AbbVie | 1 | $13 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 11 | $129 |
| Warfarin Sodium | 17 | $73 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.